Digital: Teaching An Old Dog New Tricks?
This year ’s eyeforpharma Barcelona conference made me feel old.Firstly, while chatting with [eyeforpharma Chairman] Paul Simms, I realized I have attended all but one or two since their inception. Secondly, there was a lot of discussion about digital topics and I can ’t even use Facebook correctly.Ironically, I was asked to chair the last day ’s discussion – on digital transformation. An old dog leading a discussion about new tricks.Recognizing my own ineptitude, I turned to someone who really knows about digital transformation – my son. My older son joined Tesla last year, working as a digital security expert a...
Source: EyeForPharma - March 20, 2017 Category: Pharmaceuticals Authors: Kevin Dolgin Source Type: news
Copaxone (Glatiramer Acetate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 6, 2017 Category: Drugs & Pharmacology Source Type: news
Mylan wins court ruling for Copaxone 40mg/mL patents
Global generic and specialist pharmaceuticals company Mylan has won a US District Court Ruling with regards to its Copaxone 40mg/mL patents. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 1, 2017 Category: Pharmaceuticals Source Type: news
Court invalidates 4 Teva patents for MS drug
The U.S. District Court in Delaware ruled four of Teva Pharmaceutical Industries Ltd.'s patents for Copaxone were invalid, dealing Teva its latest setback in the company's efforts to ward off generic competition for its top revenue-producing product.
The ruling sent Teva's stock price down nearly 8 percent to $31.81 per share in pre-market trading Tuesday morning.
“We intend to move forward with an immediate appeal,” said Erez Vigodman, Teva's president and CEO. “We will continue to vigorously… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2017 Category: Pharmaceuticals Authors: John George Source Type: news
US Court rules in favour of Mylan for Copaxone patents: Natco
In December 2016, the US Patent and Trademark Office (PTO) had ruled in favour of Mylan and three patents related to Copaxone 40 mg/mL were found unpatentable. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 31, 2017 Category: Pharmaceuticals Source Type: news
U.S. court rejects Teva's patent-infringement claims on Copaxone
(Reuters) - Teva Pharmaceutical Industries Ltd said on Monday a U.S. court rejected four of the Israel-based drugmaker's claims of patent infringement on its top-selling multiple sclerosis treatment. (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Teva provides financial forecast – with a caveat
Teva Pharmaceutical Industries Ltd. provided analysts Friday with its projections for revenues and earnings in 2017, but included a caveat with its numbers.
The generic drug giant said it expects revenues in the $23.8 billion to $24.5 billion range, and operating income of between $7.4 billion and $7.8 billion. Those numbers assume its Copaxone, the company’s branded multiple sclerosis drug, does not face generic competition in the United States thi s year. Teva expects sales of Copaxone, its top… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 6, 2017 Category: Biotechnology Authors: John George Source Type: news
Third U.S. patent on Teva's MS drug Copaxone invalidated
NEW YORK (Reuters) - U.S. patent officials on Thursday invalidated a third patent covering Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after cancelling two other patents on the drug last week. (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
What Genetics are Associated with Multiple Sclerosis?
Discussion
Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.”
It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Blood-borne biomarkers of MS relapse identified
NEW ORLEANS – Three potentially useful blood-based biomarkers of relapse and of the response to glatiramer acetate treatment have been identified in patients with relapsing-remitting multiple... (Source: Clinical Neurology News)
Source: Clinical Neurology News - February 24, 2016 Category: Neurology Source Type: news
Designing to Succeed
The finalists for this year’s Most Valuable Patient Initiative or Service at the 2016 eyeforpharma Barcelona Awards showcase the potential for impact when patients become collaborators in design.
Understanding the human aspects of living with a condition is in many ways less straightforward than drug development. Everyone experiences their health challenges differently, and it’s clear this can’t be designed for in a lab.
That’s why collaborating with the patient brings benefits. Here are three lessons we learned from this year’s crop of patient innovators:
1. Ongoing engagement with the patient makes iterative ...
Source: EyeForPharma - February 10, 2016 Category: Pharmaceuticals Authors: Thomas Disley Source Type: news
Should We Encourage the 'Old' Therapies for MS?Should We Encourage the 'Old' Therapies for MS?
Would patients with RRMS do better by continuing with interferon beta or glatiramer acetate treatment over the long-term, instead of switching to a newer therapeutic regimine? Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Novartis: Alcon reorg on tap for 2016
(Reuters) — Novartis (NYSE:NVS) has agreed in principle to pay $390 million to settle U.S. allegations that it used kickbacks to speciality pharmacies to push sales of some drugs, the Swiss company said today, hitting 3rd-quarter earnings.
The U.S. Justice Dept. had sued Novartis in a Manhattan federal court, saying the world’s biggest seller of prescription drugs sought illegally to boost sales of drugs covered by Medicare and Medicaid. The $390 million settlement, still pending approval, pushed Novartis’s 3rd-quarter net income down 42% to $1.8 billion.
Novartis’s underlying results also missed an...
Source: Mass Device - October 27, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Legal News MassDevice Earnings Roundup Optical/Ophthalmic Source Type: news
New Glatiramer Acetate Generic 'Equivalent' to Copaxone in MSNew Glatiramer Acetate Generic 'Equivalent' to Copaxone in MS
The GATE study, showing equivalence of the generic to the branded drug, should pave the way for the first generic of a disease-modifying treatment for multiple sclerosis in the European market. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 20, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
